SPECT-CT Imaging with 99mTc-PSMAin Patients with Recurrent Prostate Cancer | Zendy

Sonya Sergieva | Zendy; Radoslav Mangaldgiev | Zendy; Milena Dimcheva | Zendy; Kamen Nedev | Zendy; Zahary Zahariev | Zendy; Bozhil Robev | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SPECT-CT Imaging with 99mTc-PSMAin Patients with Recurrent Prostate Cancer

Author(s) -

Sonya Sergieva,

Radoslav Mangaldgiev,

Milena Dimcheva,

Kamen Nedev,

Zahary Zahariev,

Bozhil Robev

Publication year - 2021

Publication title -

nuclear medicine review

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.216

H-Index - 21

eISSN - 1644-4345

pISSN - 1506-9680

DOI - 10.5603/nmr.2021.0018

Subject(s) - medicine , prostate cancer , nuclear medicine , prostate , abdomen , biodistribution , radiation therapy , prostatectomy , radiology , cancer , urology , microbiology and biotechnology , biology , in vivo

Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with overexpression of the prostatic tumour cells. Several small molecules of PSMA ligands of inhibitors binding to the active site of PSMA were developed. [99mTc]Tc-PSMA-T4 is a new radiopharmaceutical (Polatom) for imaging loco-regional metastases and/or local relapse in patients with prostate cancer. The purpose of this work was to evaluate the clinical application of SPECT-CT imaging with [99mTc]Tc-PSMA-T4 in patients with recurrent prostate cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research